The Impact of Different Hepatitis B Virus Serological Statuses on the Safety of Different Chemotherapy Regimens in Female Breast Cancer Patients: A Within-Subject Longitudinal Study

Background: Breast cancer patients with hepatitis B virus (HBV) infection or past HBV infection face heightened risks of chemotherapy-induced hepatotoxicity and HBV reactivation (HBVr). This study aims to evaluate the impact of different HBV serological statuses on the safety of chemotherapy regimen...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancers Ročník 17; číslo 21; s. 3574
Hlavní autori: Li, Zhao-Xing, Liu, Dong-Li, Hu, Lei, Peng, Bai-Qing, Qu, Xiu-Quan, Mu, Li-Yuan, Cheng, Xiao-Chun, Qiu, Pu, Huang, Yu-Xuan, Li, Xi-Rui, Kong, Ling-Quan
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 05.11.2025
Predmet:
Analysis
Antiviral agents
Breast cancer
Cancer
Cancer patients
Cancer therapies
Care and treatment
Chemotherapy
Disease prevention
Females
Health aspects
Hepatitis B
Hepatitis B surface antigen
Hepatitis B virus
Hepatotoxicity
Infection
Infections
Leukocytes
Liver
Longitudinal studies
Oncology, Experimental
Paclitaxel
Safety and security measures
Serology
Viruses
Women
Womens health
China
breast cancer
chemotherapy safety
HBV reactivation
hepatitis B virus
hepatotoxicity
ISSN:2072-6694, 2072-6694
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background: Breast cancer patients with hepatitis B virus (HBV) infection or past HBV infection face heightened risks of chemotherapy-induced hepatotoxicity and HBV reactivation (HBVr). This study aims to evaluate the impact of different HBV serological statuses on the safety of chemotherapy regimens based on paclitaxel throughout the treatment cycle. Methods: This retrospective cohort study analyzed 4562 female breast cancer patients, categorized into three groups: 366 with HBV infection (HBsAg+), 2529 with past HBV infection (HBsAg−/HBcAb+), and 1667 without HBV infection (control group). The Primary events included liver injury, HBVr, treatment interruption, and laboratory indicator evaluation. Demographic characteristics and periodic laboratory parameters were recorded for within-subject longitudinal analysis. Results: Before chemotherapy, the incidence of liver injury was highest in the HBV-infected group (18.2%), intermediate in the past-infection group (13.2%), and lowest in the control group (12.0%). Throughout chemotherapy, the cumulative incidence of liver injury remained highest in the HBV-infected group (83.2%), compared to the past-infection (71.2%) and control (70.9%) groups. Chemotherapy interruption rates followed a similar gradient: 12.4% in the HBV-infected group, 6.9% in the past-infection group, and 5.5% in the control group. HBV-infected patients had a significantly higher risk of hepatotoxicity than controls during cycle 4 (relative risk 1.56, 95% CI 1.06 to 2.29) and cycle 5 (1.28, 1.09 to 1.75). HBVr occurred in 13 patients with HBV-infected. Conclusions: HBV serological status significantly impacts chemotherapy safety and treatment interruption. Prophylactic antiviral therapy and intensified monitoring during high-risk cycles (cycle 4 and cycle 5) are critical. These findings underscore the necessity of stratified management for HBV-affected breast cancer patients during chemotherapy.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers17213574